Alentis Therapeutics

Walking through the halls of the St. Francis Westin Hotel during the J.P. Morgan Global Health Conference, one can’t help but notice the growing presence of East Asians. Yet, when it comes to the high

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the ye

Alentis Therapeutics has raised $181.4m in a series D round to help progress its potential first-in-class Claudin-1 positive (CLDN1+) antibodies and antibody-drug conjugates (ADCs). While another cla